

FINAL RULE

Department of Health and Hospitals Board of Pharmacy

Prescription Monitoring Program – LAC 46:LIII.2901

In accordance with the provisions of the Administrative Procedure Act (La. R.S. 49:950 *et seq.*) and the Louisiana Pharmacy Practice Act (La. R.S. 37:1161 *et seq.*), the Louisiana Board of Pharmacy hereby amends the referenced rule. To provide dispensers of the referenced drugs of concern adequate opportunity to revise their recordkeeping systems to facilitate the reporting of their eligible transactions, the effective date of this amendment shall be delayed until September 1, 2010.

Malcolm J Broussard
Executive Director
Louisiana Board of Pharmacy

Louisiana Administrative Code

Title 46 – Professional and Occupational Standards

Part LIII: Pharmacists

* * *

Chapter 29. Prescription Monitoring Program

Subchapter A. General Operations

§2901. Definitions

* * *

“Drugs of concern’ means drugs other than controlled substances which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]: (1) butalbital when in combination with at least three hundred twenty five milligrams of acetaminophen per dosage unit, and (2) tramadol.

* * *

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010.